secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001628280-26-030123
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing
--------------------------------------------------------------------------------

- Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.
- Revenue $10.8M (vs <$0.1M YoY) driven by $7.5M TG Therapeutics milestone payment for Azer-Cel.
- Cash, equivalents, restricted cash $125.8M as of March 31; expected funding through 2028.
- PBGENE-HBV: 16 patients treated across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30.
- PBGENE-DMD: FDA IND clearance, Fast Track; first site (Arkansas Children's Hospital) activated, enrolling patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/0001628280-26-030123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/dtil-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer